ATE542889T1 - Neuer monoklonaler antikörper, der dazu in der lage ist, integrin-alpha-10-beta-1 zu binden - Google Patents

Neuer monoklonaler antikörper, der dazu in der lage ist, integrin-alpha-10-beta-1 zu binden

Info

Publication number
ATE542889T1
ATE542889T1 AT04727464T AT04727464T ATE542889T1 AT E542889 T1 ATE542889 T1 AT E542889T1 AT 04727464 T AT04727464 T AT 04727464T AT 04727464 T AT04727464 T AT 04727464T AT E542889 T1 ATE542889 T1 AT E542889T1
Authority
AT
Austria
Prior art keywords
integrin
monoclonal antibody
fragment
extracellular
domain
Prior art date
Application number
AT04727464T
Other languages
English (en)
Inventor
Evy Lundgren-Akerlund
Original Assignee
Xintela Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xintela Ab filed Critical Xintela Ab
Priority claimed from PCT/SE2004/000580 external-priority patent/WO2004089990A1/en
Application granted granted Critical
Publication of ATE542889T1 publication Critical patent/ATE542889T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
AT04727464T 2003-04-14 2004-04-14 Neuer monoklonaler antikörper, der dazu in der lage ist, integrin-alpha-10-beta-1 zu binden ATE542889T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0301087A SE0301087D0 (sv) 2003-04-14 2003-04-14 New monoclonal antibody
US32011203P 2003-04-16 2003-04-16
PCT/SE2004/000580 WO2004089990A1 (en) 2003-04-14 2004-04-14 New monoclonal antibody capable of binding integrin alpha 10 beta 1

Publications (1)

Publication Number Publication Date
ATE542889T1 true ATE542889T1 (de) 2012-02-15

Family

ID=20291013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727464T ATE542889T1 (de) 2003-04-14 2004-04-14 Neuer monoklonaler antikörper, der dazu in der lage ist, integrin-alpha-10-beta-1 zu binden

Country Status (3)

Country Link
US (5) US7452677B2 (de)
AT (1) ATE542889T1 (de)
SE (1) SE0301087D0 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068238B1 (de) 1998-04-02 2012-10-03 Xintela AB Ein integrin heterodimer und eine untereinheit davon
EP1589986B1 (de) * 2002-06-17 2008-10-29 Cartela R & D AB Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
WO2005073385A1 (ja) * 2004-01-29 2005-08-11 National Institute Of Advanced Industrial Science And Technology 遺伝子導入効率を上昇させるための組成物および方法
WO2006061824A2 (en) * 2004-12-06 2006-06-15 Prochon Biotech Limited Chondrocyte-based implant for the delivery of therapeutic agents
US8568761B2 (en) * 2005-07-15 2013-10-29 Cormatrix Cardiovascular, Inc. Compositions for regenerating defective or absent myocardium
EP1926459B1 (de) 2005-09-19 2015-01-07 Histogenics Corporation Zellunterstützende matrix mit eng definierter, gleichmässig senkrecht und nicht zufällig organisierter porosität und porendichte und verfahren zur herstellung davon
WO2008072000A2 (en) * 2006-12-15 2008-06-19 Xintela Ab (Se) Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8802121B2 (en) * 2009-06-02 2014-08-12 Surmodics, Inc. Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices for implantation or injection
EP2467401B1 (de) * 2009-08-19 2017-01-18 Merck Patent GmbH Antikörper zur erkennung von integrinkomplexen in einem ffpe-material
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
EP3401393B1 (de) * 2012-02-22 2020-02-19 Exostem Biotec Ltd Mikrornas zur erzeugung von astrocyten
US20170121687A1 (en) * 2014-04-23 2017-05-04 Agency For Science, Technology And Research Methods of cellular reprogramming
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
JP7059478B2 (ja) * 2015-02-16 2022-04-26 タージンタ アクチエボラグ 中枢神経系における悪性腫瘍の検出及び治療
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
DK3500859T3 (da) * 2016-08-17 2022-03-07 Xintela Ab Markør for neurale stamceller
DK3573630T3 (da) * 2017-01-27 2021-06-07 Xintela Ab Forebyggelse og behandling af skader eller sygdom i knogler og brusk
CN110809583A (zh) 2017-06-07 2020-02-18 瑞泽恩制药公司 用于内化酶的组合物和方法
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
CA3100021A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3725616A1 (de) 1987-08-03 1989-02-16 Philips & Du Pont Optical Aufbewahrungskassette fuer einen plattenfoermigen informationstraeger
EP0330506A3 (de) 1988-02-26 1990-06-20 Dana Farber Cancer Institute VLA-Proteine
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5686069A (en) 1990-10-15 1997-11-11 Mycogen Corporation Protein toxins active against lepidopteran pests
US5310874A (en) 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993021226A1 (en) 1992-04-10 1993-10-28 The General Hospital Corporation Cartilage matrix protein and methods for use
ATE162957T1 (de) 1992-12-01 1998-02-15 Merck Patent Gmbh Koordinations-katalysatorsysteme
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
AU6639394A (en) 1993-04-26 1994-11-21 Children's Medical Center Corporation A method for rapid formation and isolation of focal adhesion complexes
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5731425A (en) * 1994-10-28 1998-03-24 Eastman Kodak Company Polypeptide surface marker for cells
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
WO1997031653A1 (en) 1996-03-01 1997-09-04 Beth Israel Deaconess Medical Center Diagnosis and treatment of metastic breast carcinoma
US5843436A (en) 1996-04-22 1998-12-01 The Trustees Of Columbia University, In The City Of New York Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci
JP4382879B2 (ja) * 1996-07-12 2009-12-16 ジェネンテック・インコーポレーテッド ガンマ―ヘレグリン
US5928945A (en) * 1996-11-20 1999-07-27 Advanced Tissue Sciences, Inc. Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
EP1068238B1 (de) 1998-04-02 2012-10-03 Xintela AB Ein integrin heterodimer und eine untereinheit davon
US20030129685A1 (en) 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
WO2000051639A2 (en) 1999-03-01 2000-09-08 Halogenetics, Inc. Treatment of neoplastic diseases by radiation
AU5014700A (en) 1999-05-28 2000-12-18 Millennium Pharmaceuticals, Inc. Novel integrin alphasubunit and uses thereof
JP2001354699A (ja) 2000-06-12 2001-12-25 Teijin Ltd アンギオテンシンｉｉと結合する抗体
US6596855B2 (en) 2000-06-14 2003-07-22 Case Western Reserve University Probes for chondrogenesis
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
WO2003101497A1 (en) 2002-04-12 2003-12-11 Cartela Ab Knockout mice and their use
US6847844B2 (en) 2002-06-06 2005-01-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of data communication with implanted device and associated apparatus
ATE384079T1 (de) 2002-06-14 2008-02-15 Cartela Ab Marker für stammzellen und dessen verwendung
WO2004001004A2 (en) 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody

Also Published As

Publication number Publication date
US8563255B2 (en) 2013-10-22
US7452677B2 (en) 2008-11-18
US20120034625A1 (en) 2012-02-09
SE0301087D0 (sv) 2003-04-14
US10087253B2 (en) 2018-10-02
US20160319023A1 (en) 2016-11-03
US20140099716A1 (en) 2014-04-10
US20060127398A1 (en) 2006-06-15
US9365649B2 (en) 2016-06-14
US8012696B2 (en) 2011-09-06
US20090185978A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
ATE542889T1 (de) Neuer monoklonaler antikörper, der dazu in der lage ist, integrin-alpha-10-beta-1 zu binden
Coburn et al. Targeted mutation of the outer membrane protein P66 disrupts attachment of the Lyme disease agent, Borrelia burgdorferi, to integrin αvβ3
IL215027A (en) Anti-zb7r1 antibody, a formula containing it, and a method of increasing lymphocyte activity with its help
BR0313033A (pt) anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
IL138497A0 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
EP2534257A4 (de) Verfahren zur identifikation und isolierung von zellen zur expression von polypeptiden
WO2010091182A3 (en) Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
NZ592973A (en) Compositions and methods of using angiopoietin-like 4 protein
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
IL193212A0 (en) Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii
SG10201407938TA (en) Agents for treating disease
TW200741000A (en) Method of producing lymphocytes
SG157312A1 (en) High affinity binding site of hgfr and methods for identification of antagonists thereof
WO2006133107A3 (en) Specific binding sites in collagen for integrins and use thereof
ATE407691T1 (de) Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
ATE471169T1 (de) Engineering mit homing-faktoren
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
DE502004007244D1 (de) Verfahren zum spezifischen schnellnachweis getr nkesch dlicher mikroorganismen
DE60017263D1 (de) Verfahren zur reinigung von wasser, dafür geeignete bakterien und deren verwendung
DE60331882D1 (de) Antikörper zur Identifizierung und/oder Isolierung von wenigstens einer Zellpopulation ausgewählt aus hämatopoetischen Stammzellen, neuronalen Stammzellen, progenitoren neuronalen Zellen, Mesenchym-Stammzellen und mesenchym-progenitoren Stammzellen
ATE202117T1 (de) Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma
ATE532531T1 (de) Antiidiotypische antikörper mit neutralisierender wirkung gegen faktor viii-inhibierende antikörper
CA2522645A1 (en) New monoclonal antibody capable of binding integrin alpha10beta1